open access

Vol 2, No 5 (2013)
Review
Published online: 2013-10-25
Get Citation

Clinical remission of type 1 diabetes

Paweł Niedźwiecki, Dorota Zozulińska-Ziółkiewicz
Diabetologia Kliniczna 2013;2(5):185-190.

open access

Vol 2, No 5 (2013)
Review
Published online: 2013-10-25

Abstract

In natural history of type 1 diabetes gradual reduction of β-cell mass proceed during several years. Clinically symptoms of diabetes develop when β-cell mass reach state in which insulin secretion will be insuffi cient tokeep glycaemia in normal range. Diabetes occurs when 80–90% of islet cells will be destroyed. Pathogenesis of autoimmune destruction of β-cell is not fully understood. It includes interaction between genetic, environmental factors and appearing autoantibodies. Soon after diagnosis of type 1 diabetes and introducing insulin therapy reduction of exogenous insulin requirement is observed. This phenomenon is called clinical remission. Because of the ambiguous diagnostic criteria, identifying and comparing the frequency of occurrence of remission in type 1 diabetes is diffi cult. Despite of difference in remission criteria, they all underline residual insulin secretion. Most of remission criteria take into account following parameters: glycated hemoglobin value, daily exogenous insulin requirement and C-peptide serum level. Occurrence of remission is extremely desirable in type 1 diabetes. It influences positively on metabolic control of diabetes, reduces the risk of hypoglycaemia, improves quality of life and probably infl uence on development of chronic complications. This paper summarizes the current state of knowledge in the fi eld of clinical remission of type 1 diabetes.

Abstract

In natural history of type 1 diabetes gradual reduction of β-cell mass proceed during several years. Clinically symptoms of diabetes develop when β-cell mass reach state in which insulin secretion will be insuffi cient tokeep glycaemia in normal range. Diabetes occurs when 80–90% of islet cells will be destroyed. Pathogenesis of autoimmune destruction of β-cell is not fully understood. It includes interaction between genetic, environmental factors and appearing autoantibodies. Soon after diagnosis of type 1 diabetes and introducing insulin therapy reduction of exogenous insulin requirement is observed. This phenomenon is called clinical remission. Because of the ambiguous diagnostic criteria, identifying and comparing the frequency of occurrence of remission in type 1 diabetes is diffi cult. Despite of difference in remission criteria, they all underline residual insulin secretion. Most of remission criteria take into account following parameters: glycated hemoglobin value, daily exogenous insulin requirement and C-peptide serum level. Occurrence of remission is extremely desirable in type 1 diabetes. It influences positively on metabolic control of diabetes, reduces the risk of hypoglycaemia, improves quality of life and probably infl uence on development of chronic complications. This paper summarizes the current state of knowledge in the fi eld of clinical remission of type 1 diabetes.
Get Citation

Keywords

type 1 diabetes, clinical remission, intensive functional insulin therapy, immunointervention, physical activity

About this article
Title

Clinical remission of type 1 diabetes

Journal

Clinical Diabetology

Issue

Vol 2, No 5 (2013)

Pages

185-190

Published online

2013-10-25

Bibliographic record

Diabetologia Kliniczna 2013;2(5):185-190.

Keywords

type 1 diabetes
clinical remission
intensive functional insulin therapy
immunointervention
physical activity

Authors

Paweł Niedźwiecki
Dorota Zozulińska-Ziółkiewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl